Dynamic ordering design for dose finding in <scp>drug‐combination</scp> trials

Teng Zhang, Zhao Yang, Guosheng Yin

Type: Article

Publication Date: 2020-11-24

Citations: 0

DOI: https://doi.org/10.1002/pst.2081

View Publication

Locations

Pharmaceutical Statistics - View
PubMed - View

Similar Works

Action	Title	Year	Authors
+ PDF Chat	A clinical phase I dose-finding design with adaptive shrinking boundaries for drug combination trials	2023	Zhaohang Li Ze Xu Aijun Zhang Guanpeng Qi Zuojing Li
+	BOIN-ETC: A Bayesian optimal interval design considering efficacy and toxicity to identify the optimal dose combinations	2024	Tomoyuki Kakizume Kentaro Takeda Masataka Taguri Satoshi Morita
+	Escalation with overdose control for phase I drug‐combination trials	2013	Yun Shi Guosheng Yin
+ PDF Chat	Practical implementation of the partial ordering continual reassessment method in a Phase I combination‐schedule dose‐finding trial	2022	Pavel Mozgunov Thomas Jaki Ioannis Gounaris Thomas Goddemeier Anja Victor Marianna Grinberg
+ PDF Chat	A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents	2013	Chunyan Cai Ying Yuan Yuan Ji
+	A Bayesian Dynamic Model‐Based Adaptive Design for Oncology Dose Optimization in Phase I/<scp>II</scp> Clinical Trials	2024	Yingjie Qiu Mingyue Li
+	Effect of design specifications in dose‐finding trials for combination therapies in oncology	2016	Akihiro Hirakawa Hiroyuki Sato Masahiko Gosho
+	Bayesian optimization design for finding a maximum tolerated dose combination in phase I clinical trials	2021	Ami Takata Taiji Suzuki
+ PDF Chat	A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials	2016	Liangcai Zhang Ying Yuan
+	Applications of the partial-order continual reassessment method in the early development of treatment combinations	2024	Nolan A. Wages Patrick M. Dillon Craig A. Portell Craig L. Slingluff Gina R. Petroni
+ PDF Chat	Operating Characteristics of Restrictions on Skipping Dose Level for Adaptive Dose-Finding Method in Two-Agent Phase I Trials	2015	Akihiro Hirakawa Shigeyuki Matsui
+	A Dose-Finding Method Based on Multiple Dosing in Two-Agent Combination Phase I Trials	2014	Yasuyuki Kakurai Akihiro Hirakawa Chikuma Hamada
+ PDF Chat	Overview of Model-Based Dose-Finding Methods for Combinations of Two Agents in Phase I Oncology Trials	2014	Akihiro Hirakawa Shigeyuki Matsui
+	DODII: Bayesian Dose Optimization Design for Randomized Phase II Trials	2023	Ziji Yu Yanzhao Wang Jianchang Lin
+	Checkerboard: a Bayesian efficacy and toxicity interval design for phase I/II dose-finding trials	2020	Jun Yin Ying Yuan
+	DODII: Bayesian Dose Optimization Design for Randomized Phase II Trials	2023	Ziji Yu Yanzhao Wang Jianchang Lin
+	Accuracy and Safety of Novel Designs for Phase I Drug-Combination Oncology Trials	2022	Rong Liu Ying Yuan Suman Sen Yang Xin Qi Jiang Xiaoyun Li Chengxing Lu Mithat Gönen Hong Tian Heng Zhou
+ PDF Chat	Overview of model-assisted design for phase I dose-finding trials in oncology	2022	Koichi Hashizume Kentaro Takeda Hiroyuki Sato Akihiro Hirakawa Takashi Sozu
+ PDF Chat	Local continual reassessment methods for dose finding and optimization in drug-combination trials	2023	Jingyi Zhang Fangrong Yan Nolan A. Wages Ruitao Lin
+	Competing designs for drug combination in phase I dose‐finding clinical trials	2014	Marie-Karelle Rivière Frédéric Dubois Sarah Zohar

Works That Cite This (0)

Action	Title	Year	Authors

Works Cited by This (26)

Action	Title	Year	Authors
+	Bayesian optimal interval design for dose finding in drug-combination trials	2015	Ruitao Lin Guosheng Yin
+	Clinical Trial Design: Bayesian and Frequentist Adaptive Methods	2011	Guosheng Yin
+	Using the tolerable-dose diagram in the design of phase I combination chemotherapy trials.	1993	Edward L. Korn Ronald Simon
+	Isotone Optimization in<i>R</i>: Pool-Adjacent-Violators Algorithm (PAVA) and Active Set Methods	2009	Jan de Leeuw Kurt Hornik Patrick Mair
+ PDF Chat	Continual Reassessment Method for Partial Ordering	2011	Nolan A. Wages Mark R. Conaway John O’Quigley
+ PDF Chat	Bayesian optimal interval designs for phase I clinical trials	2014	Suyu Liu Ying Yuan
+	Continual reassessment methods in phase I trials of the combination of two drugs in oncology	1999	Andrew Kramar Anne Lebecq Emmanuel Candalh
+	Adaptive designs for dual-agent phase I dose-escalation studies	2013	Jennifer Harrington Graham Wheeler Michael Sweeting Adrian Mander Duncan I. Jodrell
+ PDF Chat	Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee	2014	Channing J. Paller Penelope A. Bradbury S. Percy Ivy Lesley Seymour Patricia LoRusso Laurence H. Baker Larry Rubinstein Erich Huang Deborah Collyar Susan Groshen
+ PDF Chat	Bayesian phase I/II adaptively randomized oncology trials with combined drugs	2011	Ying Yuan Guosheng Yin